CD40LG and neuroblastoma: A trimeric recombinant form of soluble CD40L, recently tested in Phase I studies with lymphoma or solid tumour bearing patients, showed limited toxicity, indicating the potential feasibility of this therapeutic approach in NB patients (Vonderheide et al, 2001a, 2001b).